Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
May 1st, 2007
Arrowhead Research Corporation (NASDAQ:ARWR) announced that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc., are presenting data at the 2007 American Association for Cancer Research (AACR) Annual Meeting. The presentations summarize the latest research findings on two anticancer therapies currently under development. Both therapies employ a novel delivery system called Cyclosert(TM), developed at the California Institute of Technology and exclusively licensed to Insert Therapeutics and, through Insert, to Calando. "We are pleased that our companies have outstanding data to present at this prestigious conference," said R....
Source: Cancer Weekly (2007-05-01)
|
